RT Journal Article
SR Electronic
A1 Gordon, Debra
T1 Long-Term Safety and Efficacy of Denosumab in Postmenopausal Osteoporosis
JF MD Conference Express
YR 2011
FD SAGE Publications
VO 11
IS 13
SP 12
OP 12
DO 10.1177/155989771113004
UL http://mdc.sagepub.com/content/11/13/12.abstract
AB The efficacy and safety of the antiresorptive agent denosumab on bone mineral density and fracture rates were assessed in an open-label extension, crossover trial of the original 3-year, randomized, placebo-controlled Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months study. [FREEDOM; NCT00089791; Cummings SR et al. N Engl J Med 2009].